The landscape for bioinnovation is changing. This session, hosted by the Tufts Center for the Study of Drug Development (CSDD), will examine how companies across the pharma sector are transforming their R&D business models to meet current and future market demands. This senior-level session represents the cross-functional issues that embrace not just R&D, but preclinical, clinical, regulatory, operations, portfolio management and marketing — all aspects of business development. An executive-level panel will lead this interactive session, which will cover topics including:

* What are the greatest market challenges facing the industry today? * In what ways are companies adjusting their R&D business models to meet those challenges? * How has the focus on precision and targeted therapies altered the business model? * What role do partnerships, alliances and collaborations play in the new bioinnovation landscape? * How can government further support innovation within the pharma sector?